Nurix Therapeutics Files Q1 2026 10-Q Report
Ticker: NRIX · Form: 10-Q · Filed: 2026-04-08T06:03:45-04:00
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
TL;DR
Nurix Therapeutics filed its 10-Q for Feb 28, 2026. Check financials.
AI Summary
Nurix Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending February 28, 2026. The filing includes financial statements and disclosures required for public companies. The company's mailing and business address is 1600 Sierra Point Parkway, Brisbane, CA 94005.
Why It Matters
This filing provides investors with an update on Nurix Therapeutics' financial performance and operational status for the recent quarter, crucial for investment decisions.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or unusual disclosures.
Key Numbers
- 1346546 — iXBRL 10-Q Size (Size of the main 10-Q filing document in bytes.)
- 6121370 — Complete submission text file Size (Size of the complete submission text file in bytes.)
Key Players & Entities
- Nurix Therapeutics, Inc. (company) — Filer of the 10-Q report
- 0001549595 (company) — CIK number for Nurix Therapeutics, Inc.
- 2026-04-08 (date) — Filing date of the 10-Q
- 2026-02-28 (date) — Period of report for the 10-Q
- 1600 Sierra Point Parkway, Brisbane, CA 94005 (location) — Mailing and business address of Nurix Therapeutics, Inc.
FAQ
What is the CIK number for Nurix Therapeutics, Inc.?
The CIK number for Nurix Therapeutics, Inc. is 0001549595.
When was this 10-Q filing accepted by the SEC?
This 10-Q filing was accepted on 2026-04-08.
What period does this 10-Q report cover?
This 10-Q report covers the period ending 2026-02-28.
What is the business address of Nurix Therapeutics, Inc.?
The business address of Nurix Therapeutics, Inc. is 1600 Sierra Point Parkway, Brisbane, CA 94005.
What is the SIC code listed for Nurix Therapeutics, Inc.?
The SIC code listed for Nurix Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
From the Filing
EDGAR Filing Documents for 0001549595-26-000025 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 10-Q - Quarterly report [Sections 13 or 15(d)]: SEC Accession No. 0001549595-26-000025 Filing Date 2026-04-08 Accepted 2026-04-08 06:03:45 Documents 66 Period of Report 2026-02-28 Interactive Data Document Format Files Seq Description Document Type Size 1 10-Q nrix-20260228.htm iXBRL 10-Q 1346546 2 EX-31.1 nrix-20260228x10qxex311.htm EX-31.1 10677 3 EX-31.2 nrix-20260228x10qxex312.htm EX-31.2 10667 4 EX-32.1 nrix-20260228x10qxex321.htm EX-32.1 8287 Complete submission text file 0001549595-26-000025.txt 6121370 Data Files Seq Description Document Type Size 5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20260228.xsd EX-101.SCH 42473 6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nrix-20260228_cal.xml EX-101.CAL 50920 7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nrix-20260228_def.xml EX-101.DEF 214368 8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20260228_lab.xml EX-101.LAB 578525 9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20260228_pre.xml EX-101.PRE 390533 70 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20260228_htm.xml XML 633839 Mailing Address 1600 SIERRA POINT PKWY BRISBANE CA 94005 Business Address 1600 SIERRA POINT PKWY BRISBANE CA 94005 (415) 660-5320 Nurix Therapeutics, Inc. (Filer) CIK : 0001549595 (see all company filings) EIN. : 270838048 | State of Incorp.: DE | Fiscal Year End: 1130 Type: 10-Q | Act: 34 | File No.: 001-39398 | Film No.: 26846408 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)